Question 1

What has DSIP been measured to do, and in what model?

Accepted Answer

Sorted by outcome, the record is wide and shallow. Each benefit has one or two studies behind it, and the species changes from one outcome to the next. Sleep was measured in rabbits, cats, mice and people, and the 1984 review notes that in cats, the effect on REM sleep was more pronounced, REM being dreaming sleep. Seizures, stroke and stress were measured in rats, temperature in mice, and drug withdrawal in mice. The same review lists effects on electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal. A long list like that reads as a strength. It is better read as a map of where people looked, because almost none of those outcomes was followed up, repeated by a second group, or tested in a person.

Question 2

Which sleep measures moved in people, and which did not?

Accepted Answer

The 1987 four-night study is the one to read closely, because it had a placebo and it broke sleep into parts. In those insomniac patients, the number of nocturnal awakenings, NREM sleep latency, total waking time and waking time after sleep onset were decreased under DSIP treatment. In those patients, total sleep time and NREM sleep time were increased by the peptide, and the gain came from stage 2, a light stage of sleep. The catch is in the next line: for NREM sleep time and stage 2 sleep, differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values. In plain terms, the patients were already sleeping that way before the first infusion. Deep sleep, the stage the compound is named after, did not change in that trial. That is the most important measured result on this page, and it is not the one the name promises.

Question 3

How long does it take for DSIP to work?

Accepted Answer

The answer depends on which outcome and which animal, and the studies give three very different clocks. In the 1981 insomnia study, the sleep effect arrived within a night, with the sleep enhancing capacity seen for up to 6 h of night sleep after one infusion in those patients. A 1984 summary of the human work describes a slower route, where repeated administrations indicated a buildup with normalization of sleep structure after four administrations. In rats with seizures, DSIP was slow and long, and the authors wrote that DSIP had a prolonged action, mildly reducing, but not abolishing metaphit seizure. In rats after a stroke, the battery of behavioral tests was performed on 1, 3, 7, 14, and 21 days after the blockage, so recovery was tracked over three weeks. So a reader asking how long it takes is asking a question with no single answer. Hours, nights and weeks are all in the record, each tied to a different body and a different outcome.

Question 4

Does DSIP help the body handle stress?

Accepted Answer

Stress is the second thread in this literature after sleep, and every result in it is from an animal. In rabbits, DSIP given into a vein or under the skin prevented hyposomnia after a stressful situation, meaning the animals did not lose sleep after stress. In rats put through five days of restraint, the authors concluded that long-term stress-coping effects of DSIP rest on considerable changes in the content of other oligopeptides and hormones. A 2008 rat study tested DSIP and a glycine blend called Deltaran, and found the two had largely the same actions on the nature of spike activity of neurons in brain areas tied to emotion. Every one of those is a change in a stress marker or a nerve signal rather than in how an animal behaved over time. A shift in stress chemistry in a tied-up rat is a different question from whether a stressed person copes better, and the second has not been asked in the research behind this page.

Question 5

Does DSIP ease drug or alcohol withdrawal?

Accepted Answer

There are two animal findings on opioids and one on alcohol, and they point in a direction worth knowing about without proving much. In morphine-dependent mice, DSIP into a vein, or under the skin above a threshold amount, attenuated naloxone-induced withdrawal jumping, a standard sign of withdrawal in mice. In cats, DSIP abolished the sleep suppressant effect of morphine, so the cats slept despite the opioid. The alcohol finding runs the other way round: alcohol addictism produced a substantial decrease of the DSIP-concentration in the rat brain. That last result is about what alcohol does to DSIP, not what DSIP does for someone stopping alcohol. Taken together, the work suggests DSIP and these drugs act on overlapping systems in animals. It does not establish any benefit in a person going through withdrawal, and no human study of that use appears among these sources.

Question 6

Does DSIP have anti-seizure effects?

Accepted Answer

In one rat model, yes, and the details show how modest the effect was. In rats given a chemical that makes them seize in response to loud sound, DSIP and a close variant decreased the incidence, mean seizure grade and duration of metaphit convulsions. The authors suggested DSIP and DSIP-12 may be considered as potential antiepileptics in the animal model, DSIP-12 being more efficient than DSIP. A follow-up in the same rat model found that valproate and DSIP reduced the incidence of seizure and prolonged duration of latency in a dose-dependent manner. Yet none of the applied VPA and DSIP doses eliminated the metaphit-provoked EEG signs of epileptiform activity, the seizure pattern in the rats' brain waves. Fewer and milder seizures with the abnormal brain activity still there is a partial effect in one artificial model. It is not evidence of a benefit for anyone with epilepsy.

Question 7

Does DSIP protect the brain after a stroke?

Accepted Answer

Two rat studies looked, and they measured different things. The 2021 study tested motor coordination and balance and bilateral asymmetry in rats given nasal DSIP before and after a blocked brain artery. Its authors concluded that intranasal administration of DSIP in the course of 8 days leads to accelerated recovery of motor functions in those rats. The 2008 study used a blend, glycine with delta sleep-inducing peptide combined in the neuroprotective formulation Deltaran, in rats with stress before brain ischemia. There, the survival rate of cerebral ischemia was 100% in animals given Deltaran, while death occurred in 38% of animals not given Deltaran. The survival figure belongs to a blend rather than to DSIP alone, and the 2021 result is about how fast rats regained balance rather than how much brain was saved. Neither carries over to a person recovering from a stroke without a human study.

Question 8

Does DSIP lower body temperature?

Accepted Answer

Only in one species, at two widely separated amounts, and not in the species where the effect was first reported. An earlier report had found that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight, a stimulant that drives body heat up. When a 1984 team tested it again, a reduction of the increased temperature was observed in mice but not in rats. For DSIP two active dose ranges were observed, and the peptide could not reduce the rise caused by the larger dose of 30 mg/kg d-amphetamine. A result that appears in mice, vanishes in rats, and fails against a stronger challenge is the kind of finding that needs a second lab before it means anything. It has not had one among these sources.

Question 9

Do DSIP-like peptides protect against chemotherapy damage?

Accepted Answer

Modified versions did in one animal study, and that distinction is the whole point of the answer. A 2014 study found that practically all the studied DSIP analogues were shown to exhibit considerable direct antioxidative activity in laboratory tests, and one of them, ID-6, outperformed DSIP itself. The authors concluded that the DSIP-relative peptides could be promising agents for the decrease in the toxic effects of cytostatics that are used in oncology, cytostatics being cancer drugs that stop cells dividing. The best-performing molecule was not DSIP. It was a variant with one or two building blocks swapped, tested against one cancer drug in animals. A reader buying DSIP is buying the original sequence, so this result describes a relative rather than the compound in the vial. It does not tell anyone that DSIP protects a person on chemotherapy.

Question 10

Does DSIP have anything to do with weight?

Accepted Answer

The link that turns up in searches is about a different molecule with a borrowed name. A 2009 obesity review describes the 'delta sleep-inducing peptide immunoreactor', also known as 'glucocorticoid-induced leucine zipper (GILZ)', as a possible link between body clocks and fat tissue. The review ends by calling GILZ an attractive candidate for future studies evaluating the role of circadian mechanisms in adipose tissue physiology and pathology. GILZ is a gene and the protein it makes, not the nine-unit peptide sold as DSIP. The shared name comes from how the gene was first found. So the weight claim rests on a naming accident rather than on a result. No study among the research behind this page gave DSIP and measured body weight or fat in a person, and a candidate for future study is not a finding.

Question 11

Has DSIP been studied differently in men and women?

Accepted Answer

Women and men were each studied once for hormones, and neither study was looking for a benefit. A 1993 study gave DSIP to eight healthy women with normal cycles (aged 17-36 years) and tracked growth hormone and prolactin. Its finding was that the GH and PRL circadian rhythm was not modified by DSIP administration in those women. A 1995 study in men reached a matching answer for the stress axis, writing that the data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man. When levels of the body's own DSIP were measured in the spinal fluid of 44 patients, there were no differences between men and women. None of those designs compared the sexes on a sleep outcome, so any claim of a benefit specific to men or to women has nothing underneath it in this record.

Question 12

Does a DSIP benefit in one species carry to another?

Accepted Answer

Often not, and this literature shows it more plainly than most. The group that isolated the peptide wrote that sleep-induction per se was found to be species specific, i.e. in cats REM-sleep was predominantly produced. In rabbits, by contrast, the same amounts augmented spindle-dominated, light nonREM sleep. The fever result held in mice and failed in rats, and a 1984 rat study found that a daytime infusion into the brain brought about almost no change in sleep parameters, unlike a night-time one. Rabbit, cat, mouse and rat each gave a different answer to the same question. A person is a fifth species, and the human studies gave a sixth answer, small and unclear. That is a strong reason not to borrow any animal benefit for a human claim.

Question 13

Which hoped-for DSIP benefits have not been measured?

Accepted Answer

Most of the ones it is sold for. Deep sleep in healthy adults, recovery from training, pain relief, and anti-ageing effects have no study behind them among these sources. A 2026 orthopaedic review files DSIP among recovery-enhancing agents that target circadian and mitochondrial regulators, but in the same text notes a current lack of clinical trials. A 2005 rat paper opens by saying that earlier work found DSIP has influence on insomnia, pain, adaptation to stress, epilepsy, etc. That list is a summary of earlier claims rather than a set of results, and among the research behind this page no study measures pain at all. A category label in a review, or a line in a paper's introduction, describes what people hoped rather than what anyone measured. The gap between the two is the honest answer for most of the benefits a buyer will see listed.

Question 14

What would it take to show a benefit in a healthy adult?

Accepted Answer

A study of the kind the sleep field already uses for other substances, and the 2003 review that lists DSIP spells out the bar. It describes the accepted sleep factors as ones that promote non-REMS in various species, where inhibition of their action or endogenous production results in loss of spontaneous sleep. For DSIP and the other transfer-era factors, the same review says a physiological sleep regulatory role, however, has not been determined for these substances. A 1994 study adds a clue against DSIP as a sleep signal: in five normal men, its blood levels showed no or minimal changes between a day of activity and a day of bed rest. So the work that would settle it is a placebo-controlled trial in healthy adults, under the skin, over weeks, with sleep recorded in a laboratory. That trial does not appear among these sources, which is why every benefit claim for healthy users is a hope rather than a measured result.

DSIP: what the research measured